


Respiratory Pathogens Data Aug 27-Dec 09 2017

Week Beginning	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	All Para	EV/ Rhino	Meta pneumo	Adeno	All Corona	Bocca	Mycoplasma	Chlamydia	Total Pos	POS FLU	Total	ACL %FLU	US %FLU	IL/WI %FLU	EIA %FLU
Dec 03	0	15	1	3	50	22	69	10	7	46	13	3	0	239	19	532	3.6	n/a	n/a	12.4
NOV 26	0	13	0	1	31	23	60	11	3	23	4	2	1	172	14	423	3.3	6.7	3.9	9.2
NOV 19	0	9	0	0	33	26	55	9	5	18	10	3	0	168	9	362	2.5	7.2		
NOV 12	0	3	0	0	20	26	64	7	2	23	8	1	0	154	3	421	0.7	4.4		
NOV 5	0	4	0	0	9	26	68	2	8	11	6	5	0	139	4	390	1.0	4.4	1.2	2.8
OCT 29	0	0	0	0	6	30	67	0	2	4	1	4	0	114	0	333	0.0	3.4	1.0	1.4
OCT 22	0	1	0	0	3	35	79	1	1	12	3	0	0	135	1	360	0.3	2.9	0.9	1.1
OCT 14	0	0	0	0	3	24	59	1	2	2	2	0	1	94	0	364	0.0	2.5	0.9	1.6
OCT 8	0	0	1	0	6	33	91	3	0	2	0	2	0	138	1	333	0.3	2.7	1.8	2.8
Oct 01	0	0	0	0	1	18	73	1	3	0	2	1	0	99	0	340	0.0	2.0	1.0	3.0
SEPT 24	0	0	0	0	1	24	79	0	3	3	3	0	0	113	0	286	0.0	1.6	1.2	1.7
SEPT 17	0	0	0	0	3	9	93	1	4	0	3	1	0	114	0	314	0.0	1.6	1.3	3.5
SEP 9	0	0	0	0	0	18	94	3	2	2	0	0	0	119	0	359	0.0	1.7	1.5	1.8
SEP 2	0	0	1	0	0	12	49	0	5	1	1	1	0	70	1	234	0.4	1.8	1.1	2.7
AUG 27	0	0	2	0	1	14	62	1	4	1	2	0	0	87	2	252	0.8	1.9	0.9	1.6


**Flu PCR
% Rate**

ACL RESP. PANEL - POSITIVITY RATE All targets 44.9%


- All Corona
- Chla mydia
- Myco plasma
- All Para
- Adeno
- Meta pneumo
- EV / Rhino
- RSV
- Inf B
- InfA-H3
- 2009 H1N1
- InfA-H1
- Bocca



ACL Influenza PCR POS 3.6%




ACL FLUAG EIA POS 12.4%



CDC Dec 02, 2017 Positivity rate 6.7% - Flu A – 84.5% (2009 H1N1 -9% , seasonal H3 -88%) Flu B – 15.5%


Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2017-2018 Season



A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists*


Week Ending Dec 02, 2017 - Week 48




*This map indicates geographic spread and does not measure the severity of influenza activity.

The most prevalent target as Dec 09 is; Enterovirus (positivity rate 9.7%)


ACL RMEPNL - CSF POSITIVE TARGETS





The most prevalent targets as Dec 9 are; **Giardia** and **E. histolytica**



The most prevalent target as Dec 9 are; NORO GII and GI virus





Neuraminidase Inhibitors Resistance in Samples Collected - Oct 1- Dec 2, 2017,

Per CDC website	Oseltamivir		Zanamivir		Peramivir	
	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)
Influenza A (H1N1)pdm09	48	0	43	0	48	0
Influenza A (H3N2)	243	0	243	0	190	0
Influenza B	59	0	59	0	59	0

Update Nov- 2017 PAHO/CDC

Target	Source	Period	CDC	US % POS	ACL 2017	ACL % POS	WSLH # cases	IDPH # cases
Locally acquired	US (endemic)	Jan-Nov 2017	1	0.00				
Zika virus US import	<u>US (travelers)</u>	Jan-Nov 2017	327	0.10	2	0.4	4	6
Zika virus US territory.	<u>US (local)Puerto Rico</u>	Jan-Nov 2017	583	0.16				
Dengue US import	<u>US (travelers)</u>	Jan-Nov 2017	190	0.06	4	0.9	n/a	n/a
Dengue US territory	<u>US (local)Puerto Rico⁹</u>	Jan-Nov 2017	9	0.00				
Chikungunya US import	<u>US (travelers)</u>	Jan-Nov 2017	85	0.03	4	0.9	n/a	n/a
Chikungunya US territory	<u>US (local)Puerto Rico</u>	Jan-Nov 2017	32	0.01				